AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $275M
Founded date: 2021
Investors 4
| Date | Name | Website |
| 03.11.2025 | ND CAPITAL | nd.capital |
| 19.05.2025 | Forbion | forbion.co... |
| - | Fast Track... | us.fasttra... |
| 04.07.2025 | Ono Ventur... | onoventure... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.04.2025 | Series B | $155M | - |
| 12.08.2024 | Series A | $90M | - |
| 19.09.2023 | Series A | $30M | - |
Mentions in press and media 12
| Date | Title | Description |
| 23.06.2026 | Gene Therapy Startup Targets 100,000 AATD Patients: Serapha Bio Launches With $230M | By Mike Gonzales Published: Jun 23 2026, 4:14 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 07.04.2025 | AIRNA Scores $155 Million Series B | CAMBRIDGE, MA, AIRNA, a biotech company, announced the closing of an oversubscribed $155 million Series B financing. >> Click here for more funding data on AIRNA >> To export AIRNA funding data to PDF and Excel, click here AIRN... |
| 03.04.2025 | AIRNA's $155 Million Bet on RNA Editing: A New Dawn for Genetic Medicine | In the bustling world of biotechnology, AIRNA has emerged as a beacon of hope. The Cambridge, MA-based company recently secured $155 million in Series B financing. This substantial funding round was led by Venrock Healthcare Capital Partner... |
| 02.04.2025 | AIRNA: $155 Million (Series B) Secured For RNA Editing Therapeutics | AIRNA, a biotech company pioneering RNA editing therapeutics to transform patients’ lives with rare and common conditions, announced the closing of an oversubscribed $155 million Series B financing. The funding was led by Venrock Healthcare... |
| 01.04.2025 | AIRNA Raises $155M in Series B Financing | AIRNA, a Cambridge, MA-based biotech company advancing RNA editing therapeutics, raised $155M in Series B funding. The round was led by Venrock Healthcare Capital Partners and Forbion Growth, with participation from RTW Investments, Nextech... |
| 01.04.2025 | AIRNA nets $155M series B to launch clinical test of RNA editing tech | AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 million series B fundraise. The round was led by Venrock Healthcare Capital Partners and Forbion Growth, AIRNA annou... |
| 23.02.2025 | 18th Annual European Life Sciences CEO Forum | The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of Februar... |
| 12.08.2024 | AIRNA: RNA Editing Therapeutics Company Raises $60 Million | AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, announced the successful closing of an oversubscribed $60 million financing round, bringing the total Series A fun... |
| 31.07.2024 | AIRNA Secures $90M Series A | CAMBRIDGE, MA, AIRNA announced the successful closing of an oversubscribed $90 million financing round led by Forbion. >> Click here for more funding data on AIRNA >> To export AIRNA funding data to PDF and Excel, click here AI... |
| 31.07.2024 | Airna Raises $60M Financing | Airna, a Cambridge, MA-based biotech company advancing RNA editing therapeutics to restore the health of patients with rare and common diseases, closed a $60m financing round. The financing, which brought the total Series A funding to $90m,... |
Show more